Eli Lilly bets on pipeline and selective deals to navigate the 2026 patent cliff

Headline: Lilly leans on pipeline and targeted deals as 2026 looms amid industry patent cliff

Main Topic — Lilly doubles down on R&D and selective deals to offset looming revenue gaps

Eli Lilly is intensifying focus on its late‑stage pipeline and targeted business development as 2026 emerges as a critical year for the pharmaceutical sector. With peers warning of a “patent cliff” that will strip revenues from several blockbusters, Lilly prioritises sustaining momentum from its recent diabetes and obesity franchises while accelerating candidates in adjacent therapeutic areas. Company strategy centres on converting late‑stage assets into near‑term commercial launches and securing complementary licences or bolt‑on acquisitions that shorten time to market.

Executives across the industry increasingly use language around “strategic fit” and small, early‑stage buys to shore up future growth; Lilly is among firms that combine internal R&D intensity with opportunistic external deals. The approach aims to balance the long lead times of traditional discovery with quicker routes to revenue through licensing, partnerships and selective M&A that add clinical depth without destabilising core operations. Consultants and industry strategists contend that companies able to integrate smaller assets rapidly will better absorb losses from expiring exclusivities.

Regulatory and pricing dynamics in the United States and Europe further sharpen Lilly’s playbook. As governments implement or weigh drug‑pricing measures, Lilly focuses on preparing launch strategies that protect margins while ensuring market access. The company’s planning now emphasises product differentiation, payer engagement and staged rollouts to preserve uptake for newly approved therapies even as competitors face headwinds from lost exclusivity.

Other developments — sector earnings and loss of exclusivity

Europe’s largest drugmakers report a mixed set of results this season, with earnings beats and misses but a common emphasis on 2026 as the year when 2025’s political and commercial shifts crystallise. Novartis flags an unprecedented wave of loss‑of‑exclusivity impacting revenues and profits, and AstraZeneca projects a long runway of new blockbusters through 2030, underscoring why pipelines and dealmaking dominate boardroom agendas.

Other developments — leadership and policy risks

Industry turmoil surfaces in leadership changes, exemplified by Sanofi’s sudden CEO exit after unmet expectations for R&D returns, signalling investor impatience with slow pipeline payoffs. Analysts say the interaction of prior political agreements, potential U.S./EU pricing rules and companies’ M&A appetites will determine who closes the gap in 2026 and how quickly the sector restores robust growth.